(FRE) Fresenius SE Co. KGaA - Ratings and Ratios

Fresenius SE & Co. KGaA stands as a prominent figure in the global healthcare landscape, operating through four distinct segments that cater to diverse patient needs. As a leader in renal care, Fresenius Medical Care dominates the dialysis market, offering essential products and services for patients with chronic kidney failure, including innovative dialysis machines and disposables.

The Fresenius Kabi segment is a key player in the pharmaceutical sector, specializing in IV generics and biosimilars, which are crucial for treating autoimmune diseases and cancer. Additionally, they provide enteral and parenteral nutrition, along with medical technologies such as infusion pumps and cell therapy devices, showcasing their commitment to critical care.

Fresenius Helios extends the groups reach into outpatient and inpatient care through its network of clinics and hospitals, primarily in Germany and Spain, emphasizing high-quality, data-driven healthcare services. This segment underscores their dedication to comprehensive patient care.

Fresenius Vamed complements the groups offerings by providing consulting and operational management services to healthcare facilities, enhancing infrastructure and efficiency. Their expertise extends to project development and facility management, supporting healthcare providers worldwide.

Headquartered in Bad Homburg, Germany, Fresenius boasts a rich history since its founding in 1912. With a market capitalization of over 20 billion euros, the company presents an attractive profile for investors, evidenced by its forward P/E ratio of 10.42, indicating potential growth. The price-to-book ratio of 1.10 suggests the market values its assets appropriately, while the price-to-sales ratio of 0.92 reflects efficient revenue generation.

For investors seeking stability and growth in healthcare, Fresenius offers a balanced portfolio with a strong market position and proven track record. Their diversified segments and significant R&D investments position them well for long-term success in the evolving healthcare industry. Further details can be found at their official website: https://www.fresenius.com.

Ticker Symbol: FRE
Exchange: XETRA
Type: common stock
Country Origin: Germany
GICS Sub Industry: Health Care Facilities

Market Cap or AUM: 20941.15M EUR
P/E: 45.34
P/E Forward: 10.42
P/B: 1.10
P/S: 0.92